Similar data were also observed in BPH patients challenged with Ser-Se-Ly at time 0 (group B) (Figure 1A,B); while, after 3 months of treatment (group B), a significantly reduced survivin and NAIP expression was evident (Figure 1A,B). The gene discussed is BIRC5; the disease is benign prostatic hyperplasia.